Policy / Pricing FDA Policy Tracker 2026: Psychedelics get a boost BioSpaceA year of significant policy change at the FDA brought momentum and scrutiny into the new year.Policy / PricingNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) BioSpace A year of significant policy change at the FDA brought momentum and scrutiny into the new year. Policy / PricingNeuroscienceRead full story Post navigation Previous: UK Knowledge Quarter welcomes Boehringer Ingelheim AI acceleratorNext: Beyond GLP-1Rs: emerging targets poised to gain share of obesity market Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026